ITGAL and cancer: Collectively, these findings suggest that targeting gp96/LFA-1 axis–mediated Treg infiltration into the TME is a powerful strategy to augment anti–PD-1 cancer immunotherapy by overcoming CD8+ T cell exhaustion without inducing autoimmune diseases.